Arcus Biosciences, INC. 8-K Filing
Ticker: RCUS · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1724521
Sentiment: neutral
Filing Stats: 830 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2025-11-03 16:17:26
Key Financial Figures
- $0.0001 — ich registered Common Stock, Par Value $0.0001 Per Share RCUS The New York Stock E
- $18.25 — ock "), at the public offering price of $18.25 per share (the "Offering"). Under the t
- $17.155 — on Stock from the Company at a price of $17.155 per share. On November 3, 2025, the O
- $269.7 m — received net proceeds of approximately $269.7 million, after deducting the Underwriters
Filing Documents
- d912891d8k.htm (8-K) — 29KB
- d912891dex11.htm (EX-1.1) — 188KB
- d912891dex51.htm (EX-5.1) — 12KB
- g912891g1103163406951.jpg (GRAPHIC) — 2KB
- g912891g1103163415267.jpg (GRAPHIC) — 2KB
- 0001193125-25-262589.txt ( ) — 400KB
- rcus-20251030.xsd (EX-101.SCH) — 3KB
- rcus-20251030_lab.xml (EX-101.LAB) — 17KB
- rcus-20251030_pre.xml (EX-101.PRE) — 11KB
- d912891d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated as of October 30, 2025, by and among Arcus Biosciences, Inc., Leerink Partners LLC and Goldman Sachs & Co. LLC. 5.1 Opinion of Latham & Watkins LLP. 23.1 Consent of Latham & Watkins LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ARCUS BIOSCIENCES, INC. Date: November 3, 2025 By: /s/ Terry Rosen, Ph. D. Terry Rosen, Ph.D. Chief Executive Officer (Principal Executive Officer)